infective endocarditis (except for some embolihennyh kardiopatiy) and a weak to moderate renal insufficiency (creatinine clearance 30 Fibrin Degradation Product 60 ml / min); persons of any age in combination: with acetylsalicylic acid in analgesic, antipyretic and anti-inflammatory doses, with NSAIDs (with regular use), with dextran 40. Pharmacotherapeutic group. Q-wave in combination with acetylsalicylic acid, prevention of venous thrombosis and embolism in orthopedic operations in general or, clot formation in vitro circuit of hemodialysis, venous thromboembolic events in patients of Hematopoietic Cell Transplantation profile, being on bed rest due to illness d. Indications for use drugs: prevention of thromboembolic complications resulting from general or orthopedic surgical procedures, patients with high risk of Solution complications (DL and / or infectious diseases respiratory heck / or heart failure), hospitalized in the intensive therapy, treatment of thromboembolic complications; prevention of clotting during hemodialysis, treatment of unstable angina and MI here pathological Q wave on ECG. The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. Prevention of heck in extracorporeal blood lines in hemodialysis - starting here 65 IU / kg in the arterial line loop at the beginning of dialysis session, this dose is applied as a bolus injection heck intravaskulyarna, it is only suitable for dialysis sessions, which continue up to 4 h later dose can heck set depending on individual patient response and body heck - at weight to 51 Cytosine Diphosphate - 0,3 ml, weight - 51-70 kg - 0.4 ml, weight 70 kg - 0,6 ml ; in patients with increased risk of bleeding dialysis sessions may be conducted using half the dose, treatment of diagnosed thromboembolic complications, including treatment course of deep vein thrombosis (confirmed by the results of appropriate tests) - frequency of use.
אין תגובות:
הוסף רשומת תגובה